RESEARCH TRIANGLE PARK – Durham-based Heat Biologics just got a little hotter.
The clinical-stage biopharmaceutical company reported positive interim results from a phase 2 clinical trial of its therapy to treat advanced non-small cell lung cancer (NSCLC).
Heat said the drug, HS-110 – used in combination with Bristol-Myers Squibb’s immune checkpoint inhibitor, OPDIVO – provided “substantial survival benefit” in a group of previously treated, checkpoint inhibitor naïve patients with advanced NSCLC. HS-110 is a cell-based therapy that activates patients’ immune systems to fight tumor cells.
Heat Biologics
The median progression-free survival rate in this group of trial participants was 1.8 months, with a median overall survival rate of 24.6 months, according to Heat.
(2)
INDIANAPOLIS (dpa-AFX) - Today s Daily Dose brings you news about KalVista s hereditary angioedema trial results, Heat Biologics encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida s presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance.
Read on.
1. Gamida s Presentation At TCT Meetings Catches Eyes
Shares of Gamida Cell Ltd. (GMDA) were up over 60% at $16 in extended trading Tuesday, following the presentation of full efficacy and safety results of the company s phase III clinical trial of Omidubicel in patients with hematologic malignancies undergoing a bone marrow transplant at the 2021 TCT Meetings.
Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE /
Unprecedented Long-term Survival After IO in Pretreated NSCLC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.